Prognosis of Primary Hypogonadism Without TRT
Men with untreated primary hypogonadism face progressive deterioration in sexual function, quality of life, metabolic health, and bone density, with evidence suggesting increased mortality risk compared to those receiving treatment.
Key Prognostic Outcomes Without Treatment
Mortality and Cardiovascular Risk
Untreated hypogonadism is associated with increased mortality and poorer overall health outcomes 1. The evidence demonstrates that hypogonadal men who do not receive TRT have higher 3-year mortality rates (3.6%) compared to those treated with TRT (3.1%), representing a statistically significant increased risk 1.
Sexual and Psychological Deterioration
Without TRT, men experience:
- Progressive worsening of erectile dysfunction - The 2025 EAU guidelines strongly recommend TRT as first-line treatment for hypogonadal patients with mild ED, implying that untreated patients will experience continued sexual dysfunction 2
- Declining quality of life - Studies show that TRT interruption results in worsening of aging male symptoms (AMS scores) and erectile function (IIEF-EF scores), indicating that the natural trajectory without treatment is progressive decline 3
- Persistent depressive symptoms - The guidelines recommend conventional medical therapies for severe depressive symptoms in hypogonadism, suggesting these symptoms persist without hormonal correction 2
Metabolic Consequences
The prognosis for metabolic health is particularly concerning:
- Progressive obesity - When TRT is withdrawn, weight, BMI, and waist circumference all worsen significantly 3. This suggests untreated primary hypogonadism leads to progressive weight gain
- Worsening metabolic syndrome - Functional hypogonadism correlates with obesity and metabolic disorders, creating a vicious cycle 2
- Increased inflammatory markers - C-reactive protein (CRP) worsens when TRT is interrupted, indicating ongoing systemic inflammation in untreated states 3
Urological Deterioration
Untreated hypogonadism leads to:
- Worsening lower urinary tract symptoms (LUTS) - IPSS scores deteriorate when TRT is withdrawn 3
- Increased residual voiding volume and bladder wall thickness - Both parameters worsen without treatment 3
Bone Health
While not extensively detailed in the provided evidence, the guidelines recommend conventional medical therapies for osteoporosis in hypogonadal men 2, implying that bone density deterioration is an expected consequence of untreated hypogonadism.
Cardiovascular and Cerebrovascular Events
Interestingly, untreated hypogonadal men show:
- Decreased risk of atrial fibrillation (4.0% vs 3.6% with TRT) 1
- Slightly decreased stroke risk (1.8% vs 1.6% with TRT) 1
However, this must be weighed against the overall increased mortality and morbidity from other causes.
Prostate Cancer Risk
Untreated hypogonadism is associated with significantly lower prostate cancer incidence:
- 50% decreased risk of localized prostate cancer (IRR 0.46) 4
- 80% decreased risk of metastatic prostate cancer (IRR 0.20) 4
- Overall prostate cancer incidence of 2.9% in untreated hypogonadal men vs 1.55% in those on TRT 4
This represents one of the few "protective" aspects of remaining untreated, though the clinical significance is debatable given the overall worse health outcomes.
Clinical Trajectory
The evidence strongly suggests that hypogonadism requires lifelong treatment 3. When TRT is interrupted, there is rapid deterioration across multiple domains:
- Symptoms worsen within months of treatment cessation
- Metabolic parameters deteriorate progressively
- Sexual function declines
- Quality of life decreases
The study examining TRT withdrawal and re-treatment concluded that "TRT interruption results in worsening of symptoms" and that "hypogonadism may require lifelong TRT" 3.
Important Caveats
Primary vs. Secondary Hypogonadism: The evidence provided primarily addresses hypogonadism generally, without always distinguishing primary from secondary causes. Primary hypogonadism (testicular failure) has no potential for spontaneous recovery, making the prognosis without treatment uniformly poor.
Lifestyle Modifications: While weight loss and physical activity can improve testosterone levels in functional/secondary hypogonadism, these interventions produce only modest increases (1-2 nmol/L) 2 and are unlikely to significantly alter the prognosis of true primary hypogonadism.
Individual Variability: The severity of symptoms and rate of deterioration varies among individuals, but the overall trajectory without treatment is consistently negative across multiple health domains.